Drugs / PD-1 antibody
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03393416 | Apr 2018 → Jul 2020 | gastric cancer | HRYZ Biotech Co. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06455124 | May 2024 → Jun 2026 overdue | rectal cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT03780634 | Apr 2019 → Dec 2020 | hepatocellular carcinoma | Sun Yat-sen University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03975036 | Apr 2019 → Jun 2020 | neoplasm | Henan Cancer Hospital | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-05-14 | Merck Sharp & Dohme LLC | Merck’s Investigational Anti-PD1 Antibody, MK-3475, Active in Three Different Tumor Types: New Data to be Presented at the 2014 ASCO Annual Meeting merck.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD-1 antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03780634 ↗ |
| Action | Inhibit | “MASCT-I is to add PD1 antibody in vitro cell culture process of MASCT technology to block PD1 receptor on immunocytes” NCT03393416 ↗ |
| Route | Intravenous | “200mg intravenously every 3 weeks” NCT03780634 ↗ |